Xilio Therapeutics, Inc. (XLO): Capital Expenditures
$518.0K
Year ended 2025-12-31
$670.0K
Trailing 12 months to 2026-06-30
-34.8%
3-year compound annual growth
-25.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $518.0K | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $36.0K | -92.6% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $486.0K | -74.0% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $1.87M | +69.7% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $1.10M | -49.7% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $2.19M | n/a | 2022-03-01, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $518.0K | n/m |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $346.0K | +81.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $97.9K | +47.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $562.0K | +253.5% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $718.0K | -23.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $2.0K | -80.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $518.0K | -75.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.59M | +17.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
Compare XLO, INBP, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗